Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Down 4.2 %

NASDAQ AKTX opened at $2.84 on Wednesday. The stock has a 50-day simple moving average of $1.74 and a two-hundred day simple moving average of $2.22. Akari Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $5.50.

Hedge Funds Weigh In On Akari Therapeutics

A hedge fund recently raised its stake in Akari Therapeutics stock. Omnia Family Wealth LLC lifted its holdings in Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 87,628 shares of the biopharmaceutical company’s stock after purchasing an additional 28,511 shares during the period. Omnia Family Wealth LLC owned about 1.55% of Akari Therapeutics worth $273,000 as of its most recent filing with the Securities & Exchange Commission. 5.06% of the stock is currently owned by institutional investors.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.